Types of Receptor Ligands
Receptor ligands are classified by whether they bind the receptor, whether (and how) they activate it, and the resulting biological effect. All four classes covered here—full agonist, partial agonist, antagonist, and inverse agonist—bind the receptor; they differ in the degree and direction of receptor activation, ranging from full activation (100% Emax) through none (0% Emax) to activity in the opposite direction. Understanding efficacy (Emax) versus potency (EC50) and the distinction between competitive and non-competitive antagonism ties the whole framework together.
Full Agonist
A full agonist binds the receptor and fully activates it, producing 100% of the maximal effect (Emax)—a maximal response. This is the reference against which other ligands are compared. Classic example: morphine at opioid receptors. Full agonists have both affinity (they bind) and full intrinsic efficacy (they produce the largest achievable effect).
Partial Agonist
A partial agonist binds and activates the receptor but produces less than the maximal effect (<100% Emax)—a submaximal response—no matter how high the dose. Because it occupies the receptor while producing only a submaximal effect, a partial agonist can antagonize a full agonist when both are present. Classic example: buprenorphine at opioid receptors.
Antagonist
An antagonist binds the receptor but does not activate it (0% Emax); its effect is to block agonist binding. Naloxone at opioid receptors is the classic example, used to reverse opioid overdose by displacing opioid from the receptor. Antagonism is further subdivided by mechanism: a competitive antagonist competes with agonist for the same binding site, shifts the dose-response curve to the right, can be overcome by increasing agonist concentration, and leaves Emax unchanged (naloxone). A non-competitive antagonist binds a different site or binds irreversibly, cannot be overcome by more agonist, and reduces Emax—exemplified by phenoxybenzamine, an irreversible α-blocker used in pheochromocytoma surgery where the catecholamine surge cannot overcome the blockade.
Inverse Agonist
An inverse agonist binds the receptor and produces an effect in the opposite direction of an agonist, reducing the receptor's constitutive (baseline) activity. This is distinct from a plain antagonist, which merely blocks and produces no directional effect of its own. Example: some antihistamines at H1 receptors.
High-yield
- All four ligand types bind the receptor—the difference lies in the degree and direction of receptor activation.
- Efficacy = maximum effect achievable (Emax); potency = amount of drug needed to produce an effect (EC50). A more efficacious drug produces a larger effect; a more potent drug requires a smaller dose.
- Full agonist = 100% Emax; partial agonist = <100% Emax; antagonist = 0% Emax; inverse agonist = effect opposite to agonist.
- A partial agonist can act as an antagonist in the presence of a full agonist (submaximal response, blunts the full effect).
- Competitive antagonism: same binding site, overcome by more agonist, right-shifts curve, Emax unchanged (naloxone).
- Non-competitive antagonism: different site or irreversible, not overcome by more agonist, Emax reduced (phenoxybenzamine).
- Buprenorphine (partial agonist), naloxone (antagonist), morphine (full agonist)—all at opioid receptors.
Pitfalls
- Confusing antagonist with inverse agonist: an antagonist produces no effect on its own (blocks agonist), whereas an inverse agonist actively reduces constitutive receptor activity in the opposite direction.
- Assuming a partial agonist is 'weak'—it produces submaximal Emax by nature, and in the presence of a full agonist it actually reduces the overall response.
- Thinking competitive antagonism lowers Emax—it shifts the curve right but Emax is unchanged; it is non-competitive/irreversible antagonism that reduces Emax.
- Confusing potency (EC50) with efficacy (Emax); a highly potent drug is not necessarily highly efficacious.
- Forgetting that increasing agonist dose can overcome competitive but NOT non-competitive/irreversible antagonism.
Clinical pearls
- Morphine (full), buprenorphine (partial), naloxone (antagonist) at the opioid receptor is the classic teaching triad.
- When a fixed maximum blockade persists despite a catecholamine surge in pheochromocytoma surgery, think irreversible (non-competitive) antagonist—phenoxybenzamine.
- An inverse agonist needs constitutive receptor activity to act on—it drives baseline activity down.
- A right-shifted dose-response curve with preserved Emax signals a competitive antagonist.
Frequently asked
What do all four receptor ligand types have in common?
They all bind the receptor. They differ in receptor activation: full agonists fully activate (100% Emax), partial agonists partially activate (<100% Emax), antagonists do not activate (0% Emax), and inverse agonists produce the opposite effect, reducing constitutive activity.
How can a partial agonist act as an antagonist?
Because a partial agonist produces only a submaximal response even when fully bound, when it competes with a full agonist for the same receptors it occupies sites while yielding less activation—effectively blunting (antagonizing) the full agonist's maximal effect. Buprenorphine at opioid receptors illustrates this.
What is the difference between an antagonist and an inverse agonist?
An antagonist binds but produces no effect of its own—it simply blocks agonist binding (0% Emax). An inverse agonist binds and produces an effect opposite to that of an agonist, actively reducing the receptor's constitutive (baseline) activity.
How do competitive and non-competitive antagonists differ on a dose-response curve?
A competitive antagonist shifts the curve to the right and can be overcome by increasing agonist concentration, leaving Emax unchanged (e.g., naloxone). A non-competitive antagonist binds a different site or irreversibly, cannot be overcome by more agonist, and reduces Emax (e.g., phenoxybenzamine).
Why is phenoxybenzamine used before pheochromocytoma surgery?
It is an irreversible (non-competitive) α-blocker, so the catecholamine surge released during surgery cannot overcome the blockade—the receptors remain blocked regardless of how much agonist is present.
What is the difference between potency and efficacy?
Potency is the amount of drug needed to produce an effect, measured by EC50—a more potent drug needs a smaller dose. Efficacy is the maximum effect achievable, measured by Emax—a more efficacious drug produces a larger effect.
Which opioid drugs represent each ligand class?
Morphine is a full agonist (maximal response), buprenorphine is a partial agonist (submaximal response), and naloxone is an antagonist (blocks opioid binding, used in overdose reversal)—all acting at opioid receptors.
Turn this into reasoning you can use on exam day — practice Types of Receptor Ligands on branching cases where your decisions shape the patient.